{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:00:22Z","timestamp":1789984822954,"version":"4.0.1"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    In cancer, elevated expression of the urokinase-type plasminogen activator receptor (uPAR) is a well-established adverse prognostic factor associated with enhanced tumor invasion, metastatic dissemination, cellular proliferation, and resistance to conventional therapies. Genetic ablation or silencing of uPAR has been shown to impair multiple protumorigenic functions both\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    , underscoring its pivotal role in tumor initiation, progression, and metastatic evolution. These findings establish uPAR not only as a clinically relevant prognostic biomarker but also as an attractive therapeutic target. Beyond its expression on malignant cells, uPAR is abundantly expressed within the tumor microenvironment (TME), including stromal components and immunosuppressive cell populations that actively support tumor progression and immune evasion. Notably, uPAR is highly expressed in several solid tumors characterized by\n                    <jats:italic>TP53<\/jats:italic>\n                    and\n                    <jats:italic>RAS<\/jats:italic>\n                    pathway alterations. These tumors exhibit a progenitor-like phenotype sustained by a senescence-associated, uPAR-positive stromal niche, further highlighting the contribution of uPAR to tumor plasticity and therapeutic resistance. Collectively, these observations provide a strong biological rationale for the development of uPAR-directed immunotherapeutic strategies aimed at simultaneously targeting tumor cells and the supportive TME. Such approaches may be particularly effective in aggressive and treatment-refractory malignancies, including glioblastoma, non-small cell lung cancer, and ovarian cancer. This review summarizes the current understanding of the biological role of uPAR in solid tumors and discusses the rationale for its therapeutic targeting. Furthermore, it provides a comprehensive overview of the principal uPAR-directed immunotherapeutic strategies currently under investigation, including chimeric antigen receptor (CAR) T-cell therapies, multi-epitope vaccines, monoclonal antibodies, and radioligand-based approaches. Collectively, these emerging modalities position uPAR as a versatile and broadly applicable immunotherapeutic target with the potential to address several of the major challenges associated with the treatment of solid tumors.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2026.1961182","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:01:39Z","timestamp":1789981299000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["uPAR-directed immunotherapies in solid tumors: current advances and future perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Filomena","family":"Napolitano","sequence":"first","affiliation":[{"name":"Department of Translational Medical Sciences, University of Naples Federico II","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"Montuori","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Naples Federico II","place":["Naples, Italy"]},{"name":"Center for Basic and Clinical Immunology Research (CISI), WAO Center of Excellence, University of Naples Federico II","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1039\/d1cb00007a","article-title":"Antibody recruiting molecules (ARMs): synthetic immunotherapeutics to fight cancer","volume":"2","author":"Achilli","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s43587-023-00560-5","article-title":"Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction","volume":"4","author":"Amor","year":"2024","journal-title":"Nat. Aging"},{"key":"B3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/00365521.2020.1849383","article-title":"Plasma suPAR may help to distinguish between chronic pancreatitis and pancreatic cancer","volume":"56","author":"Aronen","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13550-020-00673-7","article-title":"Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer","volume":"10","author":"Baart","year":"2020","journal-title":"EJNMMI Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"9126083","DOI":"10.1155\/jimr\/9126083","article-title":"Rational design and in silico evaluation of a multiepitope vaccine targeting the uPAR for cancer immunotherapy","volume":"2025","author":"Baghaei","year":"2025","journal-title":"J. Immunol. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-05-0946","article-title":"Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice","volume":"65","author":"Bauer","year":"2005","journal-title":"Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"120303","DOI":"10.1016\/j.cca.2025.120303","article-title":"suPAR as a biomarker of support in different clinical settings","volume":"573","author":"Belvederi","year":"2025","journal-title":"Clin. Chim. Acta"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1007\/s00018-020-03707-4","article-title":"uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells","volume":"78","author":"Biagioni","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.18632\/oncotarget.1930","article-title":"Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence","volume":"5","author":"Bifulco","year":"2014","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J. Exp. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/1354750X.2021.1910343","article-title":"Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity","volume":"26","author":"Burcs\u00e1r","year":"2021","journal-title":"Biomarkers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/14737140.2024.2328167","article-title":"Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review","volume":"24","author":"Camedda","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1194972","DOI":"10.3389\/fonc.2023.1194972","article-title":"Human antibody VH domains targeting uPAR as candidate therapeutics for cancers","volume":"13","author":"Chu","year":"2023","journal-title":"Front. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12885-017-3183-y","article-title":"u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression","volume":"17","author":"Ciavarella","year":"2017","journal-title":"BMC Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/107602960300900309","article-title":"Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer","volume":"9","author":"Cobos","year":"2003","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.molmed.2024.05.001","article-title":"Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy","volume":"30","author":"Colley","year":"2024","journal-title":"Trends Mol. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1160\/TH05-01-0054","article-title":"Plasminogen activation and cancer","volume":"93","author":"Dan\u00f8","year":"2005","journal-title":"Thromb. Haemost."},{"key":"B18","doi-asserted-by":"publisher","first-page":"26878","DOI":"10.1074\/jbc.M109.077677","article-title":"Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration","volume":"285","author":"Duriseti","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"116095","DOI":"10.1016\/j.ejca.2025.116095","article-title":"Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer","volume":"231","author":"Eefsen","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43587-025-01022-w","article-title":"Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness","volume":"6","author":"Eskiocak","year":"2026","journal-title":"Nat. Aging"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"11028","DOI":"10.3390\/ijms252011028","article-title":"Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation Factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) levels are significantly associated with endothelial injury indices in CAR-T cell recipients","volume":"25","author":"Gavriilaki","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1804038","DOI":"10.1155\/2024\/1804038","article-title":"The potential of single-chain variable fragment antibody: role in future therapeutic and diagnostic biologics","volume":"2024","author":"Gezehagn Kussia","year":"2024","journal-title":"J. Immunol. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1231623","DOI":"10.3389\/fimmu.2023.1231623","article-title":"A comparison of the binding sites of antibodies and single-domain antibodies","volume":"14","author":"Gordon","year":"2023","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4137\/BMI.S8326","article-title":"Detection of suPAR in the saliva of healthy young adults: Comparison with plasma levels","volume":"6","author":"Gustafsson","year":"2011","journal-title":"Biomark. Insights"},{"key":"B27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/antib8040054","article-title":"Antibody-drug conjugates targeting the urokinase receptor (uPAR) as a possible treatment of aggressive breast cancer","volume":"8","author":"Harel","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1016\/j.ajpath.2014.08.003","article-title":"uPAR induces expression of transforming growth factor \u03b2 and interleukin-4 in cancer cells to promote tumor-permissive conditioning of macrophages","volume":"184","author":"Hu","year":"2014","journal-title":"Am. J. Pathol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"537311","DOI":"10.3389\/fonc.2020.537311","article-title":"GPI-AP: unraveling a new class of malignancy mediators and potential immunotherapy targets","volume":"10","author":"Hussein","year":"2020","journal-title":"Front. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/cancers14010005","article-title":"Microfluidic-assisted preparation of targeted pH-Responsive polymeric micelles improves gemcitabine effectiveness in PDAC: in vitro insights","volume":"14","author":"Iacobazzi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.18632\/oncoscience.146","article-title":"HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer","volume":"2","author":"Indira Chandran","year":"2015","journal-title":"Oncoscience"},{"key":"B32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3390\/ijms23010337","article-title":"The plasminogen-activator plasmin system in physiological and pathophysiological angiogenesis","volume":"23","author":"Ismail","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1021\/cb200374e","article-title":"Reprogramming urokinase into an antibody-recruiting anticancer agent","volume":"7","author":"Jakobsche","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3350\/cmh.2024.0895","article-title":"Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target","volume":"31","author":"Ji","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.3390\/cells11223626","article-title":"Tumor microenvironment immunosuppression: a roadblock to CAR T-Cell advancement in solid tumors","volume":"11","author":"Johnson","year":"2022","journal-title":"Cells"},{"key":"B36","doi-asserted-by":"publisher","first-page":"115178","DOI":"10.1016\/j.jconrel.2026.115178","article-title":"Enhancing insulin sensitivity by reducing adipocyte senescence using uPAR-targeted nanoparticles in high-fat-diet-induced obese mice","volume":"397","author":"Jung","year":"2026","journal-title":"J. Control Release"},{"key":"B37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/antibiotics13020179","article-title":"Soluble urokinase plasminogen activator receptor (SuPAR) analysis for diagnosis of periprosthetic joint infection","volume":"13","author":"Klim","year":"2024","journal-title":"Antibiot. (Basel)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/ijc.30817","article-title":"uPA\/uPAR system activation drives a glycolytic phenotype in melanoma cells","volume":"141","author":"Laurenzana","year":"2017","journal-title":"Int. J. Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1158\/0008-5472.CAN-12-3526","article-title":"Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer","volume":"73","author":"LeBeau","year":"2013","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1166860","DOI":"10.3389\/fonc.2023.1166860","article-title":"Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: current research and future perspective","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.3390\/ijms22084111","article-title":"The urokinase receptor: a multifunctional receptor in cancer cell biology. Therapeutic implications","volume":"22","author":"Li Santi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3892\/ijo.2017.3996","article-title":"Effect of macrophages on breast cancer cell proliferation, and on expression of hormone receptors, uPAR and HER-2","volume":"51","author":"Lindsten","year":"2017","journal-title":"Int. J. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/s0022-1759(98)00189-6","article-title":"Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology","volume":"222","author":"List","year":"1999","journal-title":"J. Immunol. Methods"},{"key":"B44","doi-asserted-by":"publisher","first-page":"871","DOI":"10.7754\/Clin.Lab.2017.170110","article-title":"Prognostic role of circulating soluble uPAR in various cancers: a systematic review and meta-analysis","volume":"63","author":"Liu","year":"","journal-title":"Clin. Lab."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.7754\/Clin.Lab.2017.170726","article-title":"A preliminary study of the value of plasma microRNA-193b and soluble urokinase-type plasminogen activator receptor in identifying patients with early-stage colorectal cancer and","volume":"63","author":"Liu","year":"","journal-title":"Clin. Lab."},{"key":"B46","doi-asserted-by":"publisher","first-page":"646883","DOI":"10.3389\/fonc.2021.646883","article-title":"Serum levels of soluble urokinase plasminogen activator receptor predict tumor response and outcome to immune checkpoint inhibitor therapy","volume":"11","author":"Loosen","year":"2021","journal-title":"Front. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2184197","DOI":"10.1080\/19420862.2023.2184197","article-title":"High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions","volume":"15","author":"Louren\u00e7o","year":"2023","journal-title":"MAbs"},{"key":"B48","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s12885-017-3349-7","article-title":"Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - \u03b21 (TGF-\u03b21) and potential effects on migration and invasion","volume":"17","author":"Magnussen","year":"2017","journal-title":"BMC Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41413-020-0094-3","article-title":"uPAR antibody (huATN-658) and zometa reduce breast cancer growth and skeletal lesions","volume":"8","author":"Mahmood","year":"2020","journal-title":"Bone Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"eaea8381","DOI":"10.1126\/scitranslmed.aea8381","article-title":"uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target","volume":"18","author":"Maich","year":"2026","journal-title":"Sci. Transl. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/jpm13040688","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) in autoimmune rheumatic and non rheumatic diseases","volume":"13","author":"Manfredi","year":"2023","journal-title":"J. Pers. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.jid.2016.07.026","article-title":"A bifunctional approach of immunostimulation and uPAR inhibition shows potent antitumor activity in melanoma","volume":"136","author":"Matheis","year":"2016","journal-title":"J. Invest. Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"9388","DOI":"10.1038\/s41598-017-10062-1","article-title":"Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors","volume":"7","author":"Mauro","year":"2017","journal-title":"Sci. Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.3390\/cancers13215376","article-title":"The urokinase receptor (uPAR) as a \u201cTrojan Horse\u201d in targeted cancer therapy: challenges and opportunities","volume":"13","author":"Metrangolo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"eadq0513","DOI":"10.1126\/sciadv.adq0513","article-title":"Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models","volume":"11","author":"Metrangolo","year":"2025","journal-title":"Sci. Adv."},{"key":"B57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s43587-024-00750-9","article-title":"A chimeric peptide promotes immune surveillance of senescent cells in injury, fibrosis, tumorigenesis and aging","volume":"5","author":"Ming","year":"2025","journal-title":"Nat. Aging"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1089\/hum.2017.251","article-title":"Chimeric antigen receptor T cells: extending translation from liquid to solid tumors","volume":"29","author":"Morgan","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.3390\/cancers14174206","article-title":"Single-chain fragment variable: recent progress in cancer diagnosis and therapy","volume":"14","author":"Mu\u00f1oz-L\u00f3pez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3390\/jcm10030518","article-title":"The role of the plasminogen activation system in angioedema: novel insights on the pathogenesis","volume":"10","author":"Napolitano","year":"2021","journal-title":"J. Clin. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.3390\/ijms23116065","article-title":"Role of plasminogen activation system in platelet pathophysiology: emerging concepts for translational applications","volume":"23","author":"Napolitano","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"121260","DOI":"10.1016\/j.cca.2026.121260","article-title":"suPAR as a circulating inflammatory biomarker: time for translation into clinical practice - a systematic review","volume":"593","author":"Napolitano","year":"2026","journal-title":"Clin. Chim. Acta"},{"key":"B63","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3389\/fimmu.2018.00574","article-title":"N-Formyl peptide receptors induce radical oxygen production in fibroblasts derived from systemic sclerosis by interacting with a cleaved form of urokinase receptor","volume":"9","author":"Napolitano","year":"2018","journal-title":"Front. Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.3390\/jcm10214914","article-title":"Soluble urokinase receptor as a promising marker for early prediction of outcome in COVID-19 hospitalized patients","volume":"10","author":"Napolitano","year":"2021","journal-title":"J. Clin. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"12376","DOI":"10.3390\/ijms241512376","article-title":"Plasminogen system in the pathophysiology of sepsis: upcoming biomarkers","volume":"24","author":"Napolitano","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.3390\/ijms25063156","article-title":"The crosstalk between N-Formyl peptide receptors and uPAR in systemic sclerosis: molecular mechanisms, pathogenetic role and therapeutic opportunities","volume":"25","author":"Napolitano","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1697785","DOI":"10.3389\/fimmu.2025.1697785","article-title":"Serum profiling of uPA, PAI-1, and suPAR in systemic sclerosis: a preliminary study on analytical aspects and associations with microvascular and fibrotic manifestations","volume":"16","author":"Napolitano","year":"2025","journal-title":"Front. Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/sj.onc.1204260","article-title":"The small-GTPase RalA activates transcription of the urokinase plasminogen activator receptor (uPAR) gene via an AP1-dependent mechanism","volume":"20","author":"Okan","year":"2001","journal-title":"Oncogene"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3390\/cancers15051587","article-title":"Urokinase-type plasminogen activator receptor (uPAR) cooperates with mutated KRAS in regulating cellular plasticity and gemcitabine response in pancreatic adenocarcinomas","volume":"15","author":"Peng","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.7150\/thno.12956","article-title":"First-in-human uPAR PET: imaging of cancer aggressiveness","volume":"5","author":"Persson","year":"2015","journal-title":"Theranostics"},{"key":"B71","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0014-5793(94)00674-1","article-title":"Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins","volume":"349","author":"Ploug","year":"1994","journal-title":"FEBS Lett."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e002372","DOI":"10.1136\/jitc-2021-002372","article-title":"uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients","volume":"9","author":"Porcelli","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2967\/jnumed.124.268278","article-title":"uPAR Immuno-PET in pancreatic cancer, aging, and chemotherapy-induced senescence","volume":"65","author":"Pratt","year":"2024","journal-title":"J. Nucl. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"eabn3774","DOI":"10.1126\/sciadv.abn3774","article-title":"Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer","volume":"8","author":"Qin","year":"2022","journal-title":"Sci. Adv."},{"key":"B75","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1593\/neo.10296","article-title":"An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo","volume":"12","author":"Rabbani","year":"2010","journal-title":"Neoplasia"},{"key":"B76","doi-asserted-by":"publisher","first-page":"780641","DOI":"10.3389\/fimmu.2021.780641","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation","volume":"12","author":"Rasmussen","year":"2021","journal-title":"Front. Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000549919","article-title":"Tissue-based multiomic exploratory analysis of the urokinase plasminogen Activator\/uPAR system and matrix metalloproteinases in stroma AReactive invasion front areas-positive gastrointestinal cancers","volume":"93","author":"Reitsam","year":"2026","journal-title":"Pathobiology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2967\/jnumed.121.262866","article-title":"Prognostic value of urokinase-type plasminogen activator receptor PET\/CT in head and neck squamous cell carcinomas and comparison with 18F-FDG PET\/CT: a single-center prospective study","volume":"63","author":"Ris\u00f8r","year":"2022","journal-title":"J. Nucl. Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/j.1460-2075.1990.tb08132.x","article-title":"Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis","volume":"9","author":"Roldan","year":"1990","journal-title":"EMBO J."},{"key":"B80","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.4049\/jimmunol.1402819","article-title":"Upregulation of the N-formyl peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts","volume":"194","author":"Rossi","year":"2015","journal-title":"J. Immunol."},{"key":"B81","first-page":"34","article-title":"The urokinase\/urokinase receptor system in mast cells: effects of its functional interaction with fMLF receptors","volume":"15","author":"Rossi","year":"2016","journal-title":"Transl. Med. UniSa"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1002\/anie.201510866","article-title":"Re-engineering the immune response to metastatic cancer: antibody-recruiting small molecules targeting the urokinase receptor","volume":"55","author":"Rullo","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B83","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"B84","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.116.178970","article-title":"Safety, dosimetry, and tumor detection ability of 68Ga-NOTA-AE105: first-in-human Study of a novel radioligand for uPAR PET imaging","volume":"58","author":"Skovgaard","year":"2017","journal-title":"J. Nucl. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.36401\/JIPO-22-7","article-title":"Chimeric antigen receptor T-Cell therapy for solid tumors: the past and the future","volume":"6","author":"Srour","year":"2022","journal-title":"J. Immunother. Precis. Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"B88","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2199-10-75","article-title":"Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells","volume":"10","author":"Stewart","year":"2009","journal-title":"BMC Mol. Biol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s10096-011-1423-7","article-title":"Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome","volume":"31","author":"Tzanakaki","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"6088","DOI":"10.3390\/cancers13236088","article-title":"Overview and future perspectives on tumor-targeted positron emission tomography and fluorescence imaging of pancreatic cancer in the era of neoadjuvant therapy","volume":"13","author":"van Dam","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"109173","DOI":"10.1016\/j.biopha.2019.109173","article-title":"Basing on uPAR-binding fragment to design chimeric antigen receptors triggers antitumor efficacy against uPAR expressing ovarian cancer cells","volume":"117","author":"Wang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B92","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-019-1607-3","article-title":"Inducing and exploiting vulnerabilities for the treatment of liver cancer","volume":"574","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e0269595","DOI":"10.1371\/journal.pone.0269595","article-title":"Comprehensive analysis of the importance of PLAUR in the progression and immune microenvironment of renal clear cell carcinoma","volume":"17","author":"Wang","year":"2022","journal-title":"PLoS One"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e85349","DOI":"10.1371\/journal.pone.0085349","article-title":"Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (\u03b1M)","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"key":"B95","doi-asserted-by":"publisher","first-page":"111247","DOI":"10.1016\/j.isci.2024.111247","article-title":"Utility of plasma suPAR to identify AKI and sepsis associated AKI in critically ill children","volume":"27","author":"Xu","year":"2024","journal-title":"iScience"},{"key":"B96","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1039\/d3bm01118f","article-title":"Stromal and tumor immune microenvironment reprogramming through multifunctional cisplatin-based liposomes boosts the efficacy of anti-PD-1 immunotherapy in pancreatic cancer","volume":"12","author":"Yu","year":"2023","journal-title":"Biomater. Sci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"110561","DOI":"10.1016\/j.jbc.2025.110561","article-title":"The urokinase receptor\/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma","volume":"301","author":"Zampieri","year":"2025","journal-title":"J. Biol. Chem."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e1460","DOI":"10.1002\/onco.13750","article-title":"Plasminogen activator urokinase receptor implies immunosuppressive features and acts as an unfavorable prognostic biomarker in Glioma","volume":"26","author":"Zeng","year":"2021","journal-title":"Oncologist"},{"key":"B100","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12967-022-03329-3","article-title":"Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer","volume":"20","author":"Zhai","year":"2022","journal-title":"J. Transl. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"102209","DOI":"10.1016\/j.xcrm.2025.102209","article-title":"Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell. Rep. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12672-026-05092-z","article-title":"Progress in cell-based immunotherapies for solid tumors","volume":"17","author":"Zhang","year":"2026","journal-title":"Discov. Oncol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.cell.2026.03.002","article-title":"A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy","volume":"189","author":"Zhang","year":"2026","journal-title":"Cell."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e16597","DOI":"10.1002\/adma.202516597","article-title":"Senescence reprogramming unleashes tumor immune surveillance via coordinated gene modulation","volume":"38","author":"Zhao","year":"2026","journal-title":"Adv. Mater"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1961182\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:01:40Z","timestamp":1789981300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1961182\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":104,"alternative-id":["10.3389\/fphar.2026.1961182"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1961182","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1961182"}}